Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

Codeine Metabolism and Analgesic Effect

Introduction to Codeine Metabolism

  • Codeine is a prodrug with little to no direct analgesic effect—it must be metabolized to morphine via the CYP2D6 enzyme to provide pain relief, as recommended by the National Comprehensive Cancer Network 2, 5
  • The American College of Physicians and other guideline societies suggest that CYP2D6 poor metabolizers lack functional CYP2D6 enzyme activity and therefore cannot convert codeine to morphine, resulting in reduced or no analgesic effects 1, 2

Clinical Implications of Codeine Metabolism

  • The European Society for Medical Oncology and other organizations note that poor metabolizers still experience the full burden of codeine's adverse effects, such as nausea, vomiting, constipation, and sedation, despite receiving no analgesic benefit 1, 3
  • The National Comprehensive Cancer Network recommends avoiding codeine entirely in favor of alternative analgesics that do not depend on CYP2D6 metabolism, such as dihydrocodeine, tramadol, NSAIDs, or acetaminophen for mild pain 1, 3
  • For moderate-to-severe pain requiring opioids, the American Pain Society suggests skipping directly to morphine, hydromorphone, oxycodone, or fentanyl—these do not require CYP2D6 activation 2, 5

Ethnic and Genetic Considerations

  • The prevalence of poor metabolizers varies by ethnicity, with 5-10% in European Caucasians and lower in Asian populations, as noted by the American College of Medical Genetics and Genomics 1, 2
  • Conversely, ultrarapid metabolizers experience excessive morphine formation and potential toxicity from standard codeine doses, highlighting the need for genetic testing and personalized medicine approaches 1